RNA Atrium Therapeutics (RNA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0002093101
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
86
13F, latest reported quarter
Atrium Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Atrium Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jan 7, 2026.
- The trade is 5.9% of the 34,477 shares held after it.
- 7 other insiders sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Hughes Steven George sold about $146.1K of RNA on Jan 21, 2026; 7 other insiders sold within 30 days and 86 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jan 7, 2026.
- The trade is 9.1% of the 31,599 shares held after it.
- 7 other insiders sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Hughes Steven George sold about $208.5K of RNA on Jan 21, 2026; 7 other insiders sold within 30 days and 86 funds added in the latest 13F quarter.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Jan 7, 2026.
- The trade is 2.3% of the 277,000 shares held after it.
- 7 other insiders sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Boyce Sarah sold about $463.2K of RNA on Jan 21, 2026; 7 other insiders sold within 30 days and 86 funds added in the latest 13F quarter.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Jan 7, 2026.
- The trade is 3.0% of the 269,007 shares held after it.
- 7 other insiders sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Boyce Sarah sold about $579.1K of RNA on Jan 21, 2026; 7 other insiders sold within 30 days and 86 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Jan 7, 2026.
- The trade is 3.0% of the 85,093 shares held after it.
- 7 other insiders sold within 30 days.
- 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Flanagan W. Michael sold about $185.3K of RNA on Jan 21, 2026; 7 other insiders sold within 30 days and 86 funds added in the latest 13F quarter.152 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
86 funds bought in last quarter
more than 63% of Pharma & Biotech
Revenue
-21.9% year over year (latest quarter)
below 70% of Pharma & Biotech
Margin
-672.0% net margin (latest quarter)
below 80% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.6% of the float short (float per yahoo 2026-10-26) · 8.3 days to cover · settled 2026-09-30
more than 94% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RNA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-44.4%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RNA: institutional holders (13F)
13F holdings, latest reported quarter
1,500,000 sh
$20.2M
1,447,476 sh
$19.5M
1,283,078 sh
$17.3M
783,864 sh
$10.5M
730,831 sh
$9.8M
Congress trades in RNA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RNA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
RNA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Life Sciences and Healthcare Fund
$181.3K position · as of 2026-06-30
0.4%
NexPoint Event Driven Fund
$134.9K position · as of 2026-06-30
0.2%
Nexpoint Merger Arbitrage Fund
$1.8M position · as of 2026-06-30
0.1%
Ultra-Small Company Market Fund
$134.5K position · as of 2026-06-30
0.1%
Health Sciences Trust
$200.4K position · as of 2026-06-30
0.1%
EQ/T.Rowe Price Health Sciences Portfolio
$139.9K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Multi-phase
1 active
What changed recently
ATR 1072 in Participants With PRKAG2 Syndrome
2026-09-19 · Not Yet Recruiting → Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 86 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RNA financials
Revenue growth
-21.9%
XBRL, annual
Net margin
-672.0%
RNA Stock Sonar score 3/7 axes
Find similar shapesCompareRNA ranks highest on institutional and government (42nd percentile) and growth (30th), and lowest on risk and compliance (12th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
